Walleye Trading’s Keros Therapeutics KROS Stock Holding History

Walleye Trading’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,962	Closed	-$212K	–	4937
2023 Q1	$212K	Buy	+4,962	New	+$251K	﹤0.01%	3465

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Walleye Trading's KROS Position: Q2 2023 in Review

Walleye Trading sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 4,962 shares — an estimated $212K sold.

Walleye Trading first reported a position in KROS in Q1 2023 and held it in 1 quarter. The position peaked at $212K in Q1 2023. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

Walleye Trading reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
Walleye Trading sold 4,962 Keros Therapeutics shares in Q2 2023, an estimated $212K.
Walleye Trading first reported a position in Keros Therapeutics in Q1 2023 and held it in 1 quarter.
Walleye Trading's Keros Therapeutics position peaked at $212K in Q1 2023.
123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.